Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H48O3 |
| Molecular Weight | 456.7003 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@@H](O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C
InChI
InChIKey=NBGQZFQREPIKMG-PONOSELZSA-N
InChI=1S/C30H48O3/c1-18-10-13-26(3)16-17-28(5)20(24(26)19(18)2)8-9-21-27(4)14-12-23(31)30(7,25(32)33)22(27)11-15-29(21,28)6/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21-,22-,23-,24+,26-,27-,28-,29-,30-/m1/s1
| Molecular Formula | C30H48O3 |
| Molecular Weight | 456.7003 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Β-boswellic acid (β-BA) is one of the active triterpenoid compounds from the extract of boswellia serrate, known in Indian Ayurvedic system of medicine as Salai guggal. Beta-boswellic acid has been indicated in apoptosis of cancer cells. β-boswellic acid belonds to class of boswellic acids exhibiting anti-inflammatory activities, which are in the phase II clinical trial for study of safety and tolerability in subjects with Relapsing Remitting Multiple Sclerosis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL215 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19374837 |
23.9 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.244 μg/mL |
333 mg single, oral dose: 333 mg route of administration: Oral experiment type: SINGLE co-administered: |
Β-BOSWELLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12.48 μg × h/mL |
333 mg single, oral dose: 333 mg route of administration: Oral experiment type: SINGLE co-administered: |
Β-BOSWELLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.35 h |
333 mg single, oral dose: 333 mg route of administration: Oral experiment type: SINGLE co-administered: |
Β-BOSWELLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of Boswellia serrata in mouse models of chemically induced colitis. | 2005-04 |
|
| Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. | 2002-12 |
|
| Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. | 1998-11-17 |
|
| Mechanism of antiinflammatory actions of curcumine and boswellic acids. | 1993-03 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01450124
8 months of treatment at three times a day dose of between 400-1600 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26482008
β-boswellic acid (β-BA) significantly increases nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). HEUVCs were pretreated with β-BA (25 and 50 uM) for 24 h before being subjected to 6 h OGD then incubated with β-BA for an additional 24 h. NO production was measured by DAF-FM DA. The amount of NO was evaluated by measuring the fluorescence intensity excited at 495 nm and emitted at 515 nm.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:26:24 GMT 2025
by
admin
on
Mon Mar 31 21:26:24 GMT 2025
|
| Record UNII |
B252M1YO2V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID2057578
Created by
admin on Mon Mar 31 21:26:24 GMT 2025 , Edited by admin on Mon Mar 31 21:26:24 GMT 2025
|
PRIMARY | |||
|
300000051923
Created by
admin on Mon Mar 31 21:26:24 GMT 2025 , Edited by admin on Mon Mar 31 21:26:24 GMT 2025
|
PRIMARY | |||
|
m2628
Created by
admin on Mon Mar 31 21:26:24 GMT 2025 , Edited by admin on Mon Mar 31 21:26:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
168928
Created by
admin on Mon Mar 31 21:26:24 GMT 2025 , Edited by admin on Mon Mar 31 21:26:24 GMT 2025
|
PRIMARY | |||
|
631-69-6
Created by
admin on Mon Mar 31 21:26:24 GMT 2025 , Edited by admin on Mon Mar 31 21:26:24 GMT 2025
|
PRIMARY | |||
|
B252M1YO2V
Created by
admin on Mon Mar 31 21:26:24 GMT 2025 , Edited by admin on Mon Mar 31 21:26:24 GMT 2025
|
PRIMARY |